Author + information
- Received November 6, 2014
- Revision received December 16, 2014
- Accepted December 22, 2014
- Published online February 1, 2015.
- Mark A. Marinescu, MD∗,
- Adrián I. Löffler, MD∗,
- Michelle Ouellette, MD∗,
- Lavone Smith, MD∗,
- Christopher M. Kramer, MD∗,† and
- Jamieson M. Bourque, MD, MHS∗,†∗ ()
- ∗Department of Medicine, Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, Virginia
- †Department of Radiology and Medical Imaging, Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, Virginia
- ↵∗Reprint requests and correspondence:
Dr. Jamieson M. Bourque, Cardiovascular Division, Department of Medicine, University of Virginia Health System, Box 800158, 1215 Lee Street, Charlottesville, Virginia 22908.
Angina without coronary artery disease (CAD) has substantial morbidity and is present in 10% to 30% of patients undergoing angiography. Coronary microvascular dysfunction (CMD) is present in 50% to 65% of these patients. The optimal treatment of this cohort is undefined. We performed a systematic review to evaluate treatment strategies for objectively-defined CMD in the absence of CAD. We included studies assessing therapy in human subjects with angina and coronary flow reserve or myocardial perfusion reserve <2.5 by positron emission tomography, cardiac magnetic resonance imaging, dilution methods, or intracoronary Doppler in the absence of coronary artery stenosis ≥50% or structural heart disease. Only 8 papers met the strict inclusion criteria. The papers were heterogeneous, using different treatments, endpoints, and definitions of CMD. The small sample sizes severely limit the power of these studies, with an average of 11 patients per analysis. Studies evaluating sildenafil, quinapril, estrogen, and transcutaneous electrical nerve stimulation application demonstrated benefits in their respective endpoints. No benefit was found with L-arginine, doxazosin, pravastatin, and diltiazem. Our systematic review highlights that there is little data to support therapies for CMD. We assess the data meeting rigorous inclusion criteria and review the related but excluded published data. We additionally describe the next steps needed to address this research gap, including a standardized definition of CMD, routine assessment of CMD in studies of chest pain without obstructive CAD, and specific therapy assessment in the population with confirmed CMD.
- cardiac syndrome X
- coronary flow reserve
- coronary microvascular dysfunction
- microvascular angina
- myocardial perfusion reserve
Dr. Kramer has received research support from Siemens Healthcare. Dr. Bourque has received research support from Astellas Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received November 6, 2014.
- Revision received December 16, 2014.
- Accepted December 22, 2014.
- American College of Cardiology Foundation